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Brucella are Gram-negative intracellular pathogenic bacteria which represent a 
threat to human and animal health. Live vaccine strains are available to protect some 
animal species but no vaccines exist for human use. A DNA vaccine could potentially 
provide long lasting cell-mediated protection against human brucellosis svhile 
minimizing the virulence risks associated with live vaccines. Five DNA vaccine 
candidates, each containing a different stress response gene from B. melitensis, have 
been constructed to test the theory that stress response genes delivered as a DNA vaccine 
could provide protection against Brucella infection. A reporter vaccine expressing green 
fluorescent protein has also been constructed to facilitate vaccine trafficking studies. It is 
not yet clear whether these vaccines can provide protection against brucellosis. 
This paper is dedicated to my parents, in appreciation of the love, support, 
guidance, instruction, and everything else they have provided over the years in getting 
me to this point when I'm about to graduate and enter the "real world'* 
"Train a child in the way he should go and svhen he is old he will not depart from it" 
— Proverbs 22nd 
Thanks Mom & Dad! 
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I. INTRODUCTION 
Brucella are Gram-negative intracellular pathogenic bacteria which cause disease 
in humans and livestock. In cattle the strain B. abortus causes pregnant cows to 
miscarry, resulting in economic loss. The strain 8, melitensis causes disease in sheep and 
goats. Other species include 8. suis, 8. ovis, 8. canis, and B. maris which infect pigs, 
sheep, dogs, and dolphins, respectively'. The National Brucellosis Eradication Program 
has virtually eliminated the occurrence of brucellosis in livestock populations in the 
United States, but the potential remains for contaminating infection from wild animals. 
Vaccines are an important tool to maintain Brucella-free livestock populations. Thc live 
vaccines S19 (from B. abt&rtus) and Rcv1 (from B. melitensi s) were developed to protect 
animals against Brucella infection . More recently another vaccine strain RB51 has 2 
replaced S19 as the standard animal vaccine strain. While animal brucellosis has been 
well controlled in most developed countries through vaccmation and/or slaughter of 
infected animals, animal brucellosis remains endemic in many parts of the developing 
world and represents a threat to human health. 
Humans can contract Brucella infection through ingestion of unpasteurized dairy 
products or through direct contact with an infected animal. Human infection results in 
symptoms including chronic fever, malaise, muscle pain, anorexia, and depression. 8. 
melitensis is considered to be the most pathogenic stratn m humans . As human 3 
brucellosis is a zoonotic disease, the frequency of human infection is closely related to 
the incidence of infect&on in the animal population. A study conducted on a human 
population in Saudi Arabia where animal brucellosis was endemic showed that close to 
20"/0 of the population had been exposed to Brucella on the basis of serology . In the 
United States, the occurrence of brucellosis in humans is about 100 cases per year, less 
than . 5 cases per 100, 000 . This low number is due to the success of the brucellosis 
eradication program. However, Bruce/la also represent a potential threat to human health 
This thesis follows the style and formatting of Nature. 
as a bioterrorist agent delivered in an aerosolized form. Brucella is listed by the CDC as 
a category B select agent. Interestingly, the first biological warfare agent developed by 
the US was a weaponized form of B. suis in 1954 . A human vaccine would be desirable 6 
both to protect at risk populations in the developing world and to protect military or 
civilian personnel from bioterrorism. Although a strain derived from S19 was widely 
used in the Soviet Union in the 1950s, there are currently no vaccines approved for 7 
human use. The animal vaccine strains S19 and Revl can cause brucellosis in humans . 8 
An ideal vaccine would provide protection, minimize adverse effects, and be 
easy to deliver. In order to be protective the vaccine should stimulate a Th1 cell- 
mediated immune response . Live vaccines have traditionally been the most effective at 8 
stimulating a cellular immune response, but they can also carry the risk of causing 
discase or other adverse effects. Efforts are underway to create live vaccine strains by 
making defined knockouts of virulence genes. This represents a safer approach than 
vaccines that are attenuated by unknown mutations. However, living systems by 
definition have the ability to change and possibly revert to virulence. Additionally, living 
systems are complex and it may be difficult to predict potential adverse reactions. This 
concern becomes especially important in developing vaccines for human use as there is a 
low tolerance for adverse reactions. Subunit vaccines, while generally safer than live 
vaccines, are expensive to prepare and are not as effective at stimulating cell-mediated 
immunity or long term protection . 9 
DNA vaccines represent an alternative vaccination strategy that eliminates the 
virulence problem while at the same time maintaining the potential to stimulate 
protective cellular immunity. A DNA vaccine (Figure I) is a plasmid that contains a 
gene or genes from the pathogen that is being vaccinated against. It contains a 




I) Prokaryotic origin of replication 
2) Eukaryotic promoter 
3) Antigen gene 
4) Poly-A signal 
5) Selectable marker 
Figure 1. Simple DNA vaccine. 
It could also include genes that encode cytokines or immunostimulatory CpG sequences. 
A prokaryotic system can be used to produce the vaccine plasmid but it cannot express 
the antigen gene(s). In a cukaryotic host thc antigen gene(s) can be expressed but the 
vaccine should not be able to spread out of control or get incorporated into the host 
genome. The host cells should pick up the vaccine plasmid, express the antigen gene(s), 
and then the immune system will recognize the foreign antigen. Since the antigen gene is 
expressed within the cell, cndogcnous antigen processing pathways can present the 
antigen on the MHC complex where it can be recognized by immune cells. This process 
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Figure 2. Hypothetical mechanism of DNA vaccine action. 
The potential advantages of a DNA vaccine and the relative lack of work done in this 
area so far makes a DNA vaccine approach to brucellosis protection an attractive area 
for study. 
IL SELECTION OF CANDIDATE GENES 
After deciding to pursue a DNA vaccine approach, the next step is to choose 
which Brueella genes to test for protection. So far, seven genes have been tested for 
protection against brucellosis in an animal model ' ' ' ' ' . These results are 10, 11, I 2. t 3. 14s 5 
summarized m Table l. 
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Kurar & Splitter 1997 
AI-Mariri, et al. 2001 
Al-Mariri, et al. 2001 
Leclerq, et al. 2002 
Cassataro, ct al. 2002 
Yes, against B. Velikovsky, et al. 2002 
abortus 544 
GAPDH Thl Yes, against B. Rosinha, et al. 2002 
abortus 2308 (only 
when co-delivered 
with IL-12) 
The existing literature shows that a DNA vaccine approach could provide 
protection against Brucella, but the number of protective genes identified so far is quite 
limited. The Brttcella mellitensis genome has been sequenced'" which allows any of the 
3, 197 open reading frames to be tested at will. I did not have the time or resources to 
screen the entire genome for protective genes, although some have pursued this approach 
for other diseases in a process called expression library immunization". My goal was to 
select 4-5 genes as I thought this would be a manageable number to work with and 
testing in an animal model would essentially double the number of Brucelia genes thus 
far studied for protection. 
Celio Silva's lab in Brazil has studied the ability of heat shock proteins to protect 
against Mycobacteria infection . Heat shock proteins are proteins upregulated under 18 
cellular stress conditions. They generally function as chaperones which help to mamtain 
other proteins in the correct conformation and protect them from denaturation. Silva's 
lab found that a DNA vaccine encoding HSP 65 gave protection against M. tuberculosis 
that was better than the standard Bacillus Calmette Guerin (BCG) live vaccine even 
eight months after vaccination . Tuberculosis, like BruceBa, is an intracellular pathogen 19 
so they may share some of the same types of antigenic proteins. 
MHC II molecules become associated with antigen in endosomes . Brucella 20 
infect macrophages by uptake in endosomes. Macrophages usc low pH and reactive 
oxygen intermediates to break down the contents of endosomes and lysosomes. Brucella, 
however, resist this degradation by upregulating heat shock and other stress response 
genes. It is hypothesized that stress response genes in Bvucella would make good 
vaccine candidates as they are upregulated in the same cellular compartment that sclccts 
antigens for presentation to the immune system, and they have been shown to be 
protective in another species of intracellular pathogenic bacteria. 
I decided to pick five stress response genes to test as DNA vaccines against 
brucellosis. I initially searched GcnBank for Brucella heat shock genes but later 
narrowed my search to select stress response genes based on two important criteria: 
1) Genes which had been shown experimentally to be upregulated under heat, 
acid, or oxidative stress conditions 
2) Genes which had not previously been tested for protection as DNA vaccines 
I obtained the experimental regulation data from Teixeira-Gomes, Cloeckaert, and 
Zygmunt (2000) and Lin and Ficht (1995) ' . The candidate genes selected arc 
summarized m Table 2. 
Table 2. DNA vaccine candidate enes. 
Gene Predicted size Function Upre ulation GenBank ID 
AapJ 37. 1 kDa Amino acid heat shock AE009560 
binding gi17983192 
acid pH Asp24 20. 4 kDa Calcium AF014823 
binding gi2353000 
CuZn SOD 18. 2 kDa Superoxide oxidative stress AE009694 
dismutase gil7984757 
DnaK 68. 7 kDa Chaperone heat shock, acid AE009633 
pFI gi17984056 
Mn SOD 22. 5 kDa Superoxide heat shock AE009560 
dismutase gi17983362 
AapJ, CuZn SOD, and DnaK have been shown to be immunogenic in sheep '. 
After making the decision to test these Brucella stress response genes I began the work 
of building the actual DNA vaccine constructs. 
III. CONSTRUCTION OF DNA VACCINE VECTORS 
Introduction 
A rationally designed DNA-based vaccine approach allows a great variety of 
features to be included in the vaccine design. Such options include encoding multiple 
antigen genes, cytokines to modulate immune response, CpG or other 
immunostimulatory sequences, and tags to target proteins for trafficking. For the sake of 
simplicity and clarity in interpreting the results of future protection experiments I 
decided to construct basic vaccine vectors. I built 5 vectors each carrying a single gene 
under the control of the human cytomegalovirus (CMV) promoter. This promoter has 
been used successfully in many DNA vaccine cxpcriments. I chose pVAXI from 
Invitrogen as the vector backbone because it was designed to comply with FDA 
guidelines for developing DNA vaccines ' . Genes were amplified by PCR from thc B. 
melitensis genome and cloned into pVAX1. The resulting constructs were verified by 
digestion and sequencing. 
Materials aud methods 
Bacteria. E, coli strains DHSu or Top10 were used for plasmid propagation. E, coli were 
grown at 37' in LB broth or on LB agar plates containing 1001tg/ml kanamycin when 
appropriate. B. melitensis strain 16M was grown at 37' under BL-3 conditions. This 
culture was spotted onto FTA cards (Whatman, Clifton, NI) to provide genomic DNA 
for PCR. 
~PCR t . PCRpt t pttfy dg d tg dgyd d ttgpt 
design tools in MacVector or Biology Workbench (workbench. sdsc. edu) using the 
GenBank sequence (Table 2). The forward primers were designed to contain a Kozak 
sequence for correct eukaryotic translation initiation . A BamH1 restriction site was 
't 5 
also added to the forward primers and an EcoRV site to the reverse primers to facilitate 
directional cloning. These primers (Table 3) were ordered from Invitrogen (Carlsbad, 
CA). 
Table 3. PCR primers. 
Primer 
AapJ FWD (TAF 283) 
AapJ REV (TAF 284) 
Asp24 FWD (TAF 285) 
Asp24 REV (TAF 286) 
CuZnSOD FWD (TAF 287) 
CuZnSOD REV (TAF 288) 
DnaK FWD (TAF 289) 
DnaK REV (TAF 290) 
Mn SOD FWD (TAF 302) 












PCR. The iCycler (Bio-Rad, Hercules, CA) thermal cycler was used to PCR amplify 
each gene. A temperature gradient was used to obtain optimal PCR. FastStart Taq 
(Roche, Basel, Switzerland) and associated reagents were used to amplify each gene 
from a 1. 2mm punch of an FTA card matrix (Whatman, Clifton, NJ) containing genomic 
B. melitensis template DNA. 
Ml I I I g. M I I I g fPCR plfldg t PVAXIII t g 
Carlsbad, CA) was carried out according to the protocols found in Molecular Cloning '. 
PCR amplified genes were double digested with BamH1 and EcoRV. pVAX was double 
digested with BamH1 and EcoRV and dephosphorylated with shnmp alkaline 
phosphatase (Roche, Basel, Switzerland). Vector and insert were ligated using T4 DNA 
ligase (Promega, Madison, WI) for 2 hours at room temperature. The ligation was 
transformed into chemically competent E. coli and plated on LB/kan. This process 
resulted in the constructs pVAX-AapJ, pVAX-Asp24, pVAX-CuZnSOD, pVAX-DnaK, 
and pVAX-MnSOD. 
Di estion verification. For each transformation, 5-10 colonies able to grow on LB/kan 
were picked to verify the presence of the hypothetical vaccine construct. Plasmid DNA 
was collected using a miniprep kit (Sigma, St. Louis, MO). Undigested plasmid DNA 
and plasmid DNA double digested with BamH1 and EcoRV was run on a 1'/B (w/v) 
agarosc gel and visualized for the presence of the vector backbone and the expected size 
insert. 
~S. S q 1gp1 h d th 77 dBGH q pVAX1 
ordered from Invitrogcn (Carlsbad, CA). Thc primer 5'-taatacgactcactatacgg-3' (TAF 
304) allows forward (T7) sequencing and 5'-tagaaggcacagtcgagg-3'(TAF 305) allows 
reverse (BGH) sequencing of the insert region. A 15 ltl sequencing reaction containing 6 
ltl Big Dye, 500ng plasmid template, and 5pmol of primer was carried out in the iCycler 
(Bio-Rad, Hercules, CA). The sequence was determined by the VTPB sequencing core 
(Texas ARM). 
Results 
Five vaccine vectors, pVAX-AapJ, pVAX-Asp24, pVAX-CuZnSOD, pVAX- 
DnaK, and pVAX-MnSOD, were successfully constructed. Figures 3 and 4 show that 
each construct contains the expected insert. 
10 
Aap J FWD TAF 283) 
AapJ 
A pJ REV TAF 284) 
Cu-Zn SOD REV (TAF 288) 
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Figure 3. PCR amplified gene inserts. 
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Construct Expected fragment 
I) pVAX-AapJ 1227bp 
2) pVAX-Asp24 858bp 
3) pVAX-CuZnSOD 563bp 
4) pVAX-DnaK 2034bp 
5) pVAX-MnSOD 640bp 
6) pVAX 
Figure 4. Digests of vaccine vectors. 
The forward and reverse sequence for each construct was aligned to thc GcnBank 
sequence and found to match up as expected. In particular, the presence of the start 
codon and surrounding Kozak sequence was verified. The sequence analysis suggests 
that the vaccine vectors should be able to express the cloned gene. 
IV. TESTING THE VACCINES FOR EXPRESSION 
Introduction 
The vaccines contain a eukaryotic promoter and a gene in the correct orientation 
with a eukaryotic translation mitiation sequence, so eukaryotic cells should be able to 
express the antigen gene. However, in order to have confidence in the results of in vivo 
efficacy tests, it is necessary to demonstrate that the vaccines do in fact express thc 
correct protein in eukaryotic cells. The strategy for testing for expression m eukaryotic 
cells is to transfect the vaccine plasmids into tissue culture and then to detect the protem 
in cell lysates by western blot. 
Materials and methods 
Tissue culture. Baby hamster kidney (BHK-21) cells were grown in DMBM 
supplemented with 10'/0 FBS and non-essential amino acids. Tissue culture work was 
performed in a sterile hood. Cells werc seeded at a density of 2x10 cells/cm in 75cm' 
tissue culture flasks and grown at 37' with 5'/0 carbon dioxide. 
Transfection. BHK-21 cells were seeded in 24 well plates at a density of 1 x10 
cells/well. On thc following day cells were transfected according to the Lipofectamine 
2000 protocol with 100 fil of lipoplexes containing . 8- 1 lig plasmid DNA and 2-3frl 
Lipofectamine 2000 (Invitrogen, Carlsbad, CA). Cells werc transfected with the vaccine 
plasmids or pVAX-lacZ as a positive control. After 48 hours, cells were lysed and 
prepared for electrophoresis m SDS loading gel according to the Molecular Cloning 
protocol '. The control cells were stained with X-gal according to the Invitrogen 
protocol and observed under a microscope. 
12 
Protein electro horesis. SDS-PAGE gels of the cell lysates were run using the reagents 
and protocols of the Mini-Protean II system (Bio-Rad, Hercules, CA). The proteins were 
run on 12'/o polyacrylamide gels prepared according to the Mini-Protean II protocols or 
on precast ReadyGels (Bio-Rad, Hercules, CA). Gels were stained with Coomassie to 
visualize proteins or were used for blotting. 
Protem transfer. Proteins were transferred from the gels to Immobilon-P membrane 
(Millipore, Billerica, MA) by semi-dry transfer using the Immobilon-P protocol. 
Western blots. Membranes were blocked with 3'/o gelatin m TBST. Blots were incubated 
with a I:500 dilution of serum containing primary antibody and I'/o gelatin in TBST 
overnight. Membranes were washed 4-5 times for 2 minutes with TBST. Blots were 
incubated 2 hours with a I:1000 or 1:5000 dilution of secondary antibody conjugated to 
horseradish peroxidase (KPL, Gaithersburg, MD) prepared in I '/o gelatin in TBST. Blots 
were washed 4-5 times for 2 minutes with TBST and then TBS. Blots were visualized 
usmg TMB I-component membrane pcroxidase substrate (KPL, Gaithcrsburg, MD). 
Results 
Successful transfection was verified by the pVAX-LacZ positive control plasmid. 
50-70'/o transfection efficiencies were observed (Figure 5). Serum from a B. melirensis 
infected goat was used as the source of primary antibody to detect protein expression in 
the tissue culture cells (Figure 6). A goat exposed to Brucella would presumably make 
antibodies against a large number of Brucella proteins. However, attempts to use this 
serum were not effective in identifying the expected proteins. There are at least two 
possible explanations for this result. Antibodies against the vaccine gene proteins may 
not be present in the infected goat or prcscnt only at low levels. 
13 
Figure 5. Transfected cells. BHK-21 cells transfected with pVAX-LacZ (left) or 
untransfected (right) stained with X-gal. 
132. 0 
78. 0:~'= 
1 2 3 4 5 6 2 3 4 5 6 
45. 7:ir='' 
18. 4 
7. 6 ~ 
I) Nontransfected 4) Transfected with pVAX-CuZnSOD 
2) Transfected with pVAX-AapJ 5) Transfected with pVAX-DnaK 
3) Transfected with pVAX-Asp24 6) Transfected with pVAX-MnSOD 
Figure 6. Protein gel and western blot. Protein gel stained with Coomassie (left) and 
western blot using B. melitensis infected goat sera (right). 
A lack of antibodies against these proteins does not necessarily imply that the proteins 
are not good antigens. If the proteins are intended as T-cell antigens to stimulate a cell 
mediated response, the lack of a humoral rcsponsc may be irrelevant. Alternatively, 
14 
antibodies against the proteins may be present in the sera, but the vaccines may not be 
expressing detectable amounts of protein. This particular experiment did not have 
sufficient controls, so the results were all or nothing. Unfortunately the results are 
inconclusive. Additionally, the blot showed a large amount of non-specific binding to 
proteins from the BHK cells. The background could potentially be reduced through some 
type of preabsorption step, but this was not attempted. 
The western blot was repeated with sera from a rabbit exposed to Asp24 protein. 
This specific primary antibody should be able to determine whether or not BHK cells 
could express Asp-24 from the pVAX-Asp24 vaccine. The western blot was performed 
twice with a negative control (nontransfected BHK-21 lysate), a positive control (8. 
melitensis protein extract), and the unknown (BHK-21 transfected with pVAX-Asp24). 
Neither attempt showed binding to the unknown or to the positive control. This result 
combined with the non-specific binding observed in thc other cxpcrimcnt suggests that 
there may be something wrong with my blotting technique. I lowever, no specific actions 
were taken to induce Asp24 expression in the 8, melitensis positive control. It is possible 
that the postitivc control was not expressing detectable levels of Asp24. A new positive 
control should be made from a culture grown in low pH conditions to be sure of 
inducing Asp24 expression. 
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V. REPORTER FOR DNA VACCINE TRAFFICKING EXPERIMENTS 
Introduction 
The method whereby DNA vaccines provide protection is still not well 
understood. The ability to combine data on the efficacy of a vaccine with knowledge of 
how the vaccine is nafficked could provide a better understanding of the protective 
mechanism. A DNA vaccine encoding green fluorescent protein would allow one to 
identify the types of cells that pick up the vaccine plasmid under different delivery 
conditions. Tissue samples could be taken from thc injection site, lymphatic system, or 
any other part of the body. Cells expressing GFP could be observed by fluorescence 
microscopy or flow cytometry. This approach could be combined with fluorescent 
antibodies to distinguish specific cell types that take up the vaccine. 
Materials and Methods 
Construction of VAX-GFP. A 959 bp BamH1 EcoRV fragment containing the GFP 
gene was excised from pLEGFP-Nl (Bio-Rad, Hercules, CA). This fragment was cloned 
into the multiple cloning site of pVAX1 using methods similar to those described above. 
Success in building the desired construct was verified by digestion as descnbed above. 
Testin VAX-GFP. pVAX GFP was transfected into BHK-21 cells as described above. 
48 hours post transfection the cells were visualized by fluorescence microscopy and 
compared to a nontransfected control. 
The results of thiis expetdmcnt show that pVAX-GFP is a functiional construct 
Fiigure 7. Expression of pVAX-GFP. 
Top left: pVAX-GFP transfected cells (fluorescent view) 
Top right: pVAX-GFP transfected cells (brighttIeld view) 
Bottom left: Nontransfected cells (fluorescent view) 
Bottont right: Nontransfected cells (brightfield view) 
Five DNA vaccines, each encoding a different stress response protein from B. 
Ine11tensls were const ucted to test the h)'pothesls tltat stress response genes deltvered as 
DNA vaccines could protect against 8t. uce))a infection. The properties of these vaccine 
17 
constructs have been partially characterized, but it is not yet clear whether these vaccines 
can be expected to perform as designed when delivered in an animal study. Additionally, 
the primary goal of testing these vaccines for protection agamst brucellosis in an animal 
model has not yet been achieved. 
The verification of protein expression from the vaccines has been hindered by the 
lack of specific antibodies against the proteins of interest. In order to carry out western 
blots to detect the proteins in the cell Iysates it will be necessary to make specific 
antibodies. To accomplish this, the genes will need to be cloned into a bacterial 
expression vector, possibly using a poly histidine tag to aid in affinity chromatography 
purification. The purified protein can then be injected into animal and thc sera 
containing antibody can be collected. This process may take a significant amount of 
time. 
Alternatively, advances in proteomics technologies may offer another approach 
to detect the presence of these proteins in cell lysates. Dr. Russel's lab in the chemistry 
department at Texas ARM has explored the use of MALDI-TOP mass spectrometry to 
detect individual proteins present in a mixture of proteins . This technology may be 27 
improved to detect individual proteins present in whole cell lysates. Proteins are digested 
into peptide fragments. These peptide fragments are ionized and the mass spectrum is 
taken for each peptide. These spectra are compared to a database of known spectra for 
defined peptides. Software converts this data to a list of the proteins present in the 
sample. 
Once protein expression bas been verilied, these vaccines should bc tested in an 
animal model for protection against brucellosis. Current research suggests that a massive 
dose of DNA (100 pg for a mouse) delivered by intramuscular injection can stimulate a 
2S Th1 immune response . A Th1 immune response is believed to be important for 
protection against brucellosis, so delivery of the DNA vaccines by i. m. injection would 
be a good place to start. One could also test oral delivery, possibly in food grade 
bacteria, or targeted delivery using liposomes or other methods. If desired, the vaccines 
could be tested before expression in tissue culture is confirmed. Detection of expression 
18 
in tissue culture could be carried out later to determine why a particular vaccine did or 
did not provide protection. 
Experiments using the pVAX-GFP plasmid in an animal model could also begin 
right away to understand how delivery method affects which cells pick up the vaccine 
plasmids. Experiments designed to target the vaccines to specific cell types could also be 
conducted. An understanding of how plasmids are moved through the body, taken up 
and expressed, or delivered to particular cell types would provide information that would 
assist in designing an optimal protection experiment. 
It is unfortunate that time and unforeseen difficulties have not yet allowed the 
vaccines constructed in this work to be tested for protection in an animal model. 
However, the work presented here provides a foundation for thc future development of 
DNA vaccines and delivery strategies to protect against brucellosis. 
19 
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